Beier and Beeh 17. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budes- onide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81. 18. Calverley PMA, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–919. 19. Calverley PMA, Anderson JA, Celli BR, et al. Salmeterol and flutica- sone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. 20. Calverley PMA, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456. 21. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404. 22. Donohue JF, Van Noord JA, Langley SJ, et al. Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. Eur Respir J. 2001;18:26s. 23. Briggs JDD, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397–404. 24. Richter K, Stenglein S, Mocke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration. 2006;73:414–419. 25. Vogelmeier C, Kardos P, Harar Si, et al. Formoterol mono- and com- bination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511–1520. 26. Beeh KM, Hederer B, Glaab T, et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J COPD. 2009;4:119–124. 27. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007;29:575–281. 28. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharma- cological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)- 1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006;317:762–770. 29. Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacologi- cal characterization of indacaterol, a novel once daily inhaled beta2 adrenoceptor agonist, on small airways in human and rat precision cut slices. J Pharmacol Exp Ther. 2008;324:270–275. 30. Lombardi D, Cuenoud B, Kraemer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacology properties? Eur J Pharm Sci. 2009;38:533–547. 31. Rosethorne E, Turner R, Fairhurst R, Charlton S. Efficacy is a contribut- ing factor to the clinical onset of bronchodilation of inhaled beta(2)- adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 2010; 382:255–263. 32. Tarral A, Fauchoux N, Knight H, et al. Safety and tolerability of multiple- dose indacaterol, a novel.2-agonist, in patients with mild asthma. Eur Respir J. 2005;26(Suppl 49):253s. 33. Duvauchelle T, Elharrar B, Knight H, et al. Single-dose indacaterol, a novel 24-hour.2-agonist, is well tolerated in patients with mild asthma. Eur Respir J. 2005;26(Suppl 49):253s. 34. Perry S, Woessner R, Kaiser G, et al. Pharmakokinetics of indacaterol after single and multiple inhaled doses. Am J Respir Crit Care Med. 2010;181:A4420. 35. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of inda- caterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102:1033–1044. 36. Beeh KM, Derom EY, Kanniess F, et al. Indacaterol, a novel once-daily 2-agonist, provides sustained 24-hour bronchodilator efficacy in asthma. Eur Respir J. 2007;29:871–878. Dovepress 37. Beier J, Beeh KM, Pascoe S, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009; 22:492–496. 38. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a novel long-acting {beta}2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. Feb 24, 2011. [Epub ahead of print]. 39. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273–279. 40. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 µg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulmonary Medicine. 2010;10:11. 41. LaForce C, Aumann J, de Teresa Parreno L, et al. Sustained 24-hour efficacy of once daily indacaterol (300 mcg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther. 2011;24:162–168. 42. Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011. In press, corrected proof. 43. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long- acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473–479. 44. Donohue JF, Decramer M, Owen R, et al. Indacaterol provides significant bronchodilation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use. Am J Respir Crit Care Med. 2010;181:A4438. 45. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155–162. 46. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded com- parison with tiotropium. Respiratory Research. 2010;11(1):135. 47. Dunn LJ, Buhl R, Lassen C, et al. Blinded 12-week comparison of once- daily indacaterol and tiotropium in COPD. Chest. 2010;138:719A. 48. Kleerup E, Williams J,Yegen U, et al. The effect of indacaterol once-daily on health-related quality of life, symptoms and rescue medication use in moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of six month data. Am J Respir Crit Care Med. 2010;181: A4429. 49. Siler T, Williams J, Yegen U, et al. The effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med. 2010;181: A4430. 50. Mahler DA, Buhl R, Owen R, et al. Indacaterol provides effective bronchodilation in patients with chronic obstructive pulmonary disease irrespective of patient age (,65 or .65 years). Am J Respir Crit Care Med. 2010;181:A4456. 51. Kleerup E, D’Urzo A, Owen R, et al. Once-daily indacaterol provides significant bronchodilation in chronic obstructive pulmonary disease patients irrespective of baseline reversibility. Am J Respir Crit Care Med. 2010;181:A4439. 52. Chuchalin A, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med. 2007;101:2065–2075. 53. Yang WH, Martinot JB, Pohunek P, et al. Tolerability of indacaterol, a novel once-daily 2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol. 2007;99:555–561. 54. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily 2-agonist, in patients with COPD: a 28-day randomised, placebo-controlled clinical trial. Pulm Pharmacol Ther. 2007;20:740–749. 242 submit your manuscript | www.dovepress.com Dovepress International Journal of COPD 2011:6